In 40 seconds
Vascular dementia (VaD) is caused by cumulative cerebrovascular injury — stroke, lacunes, white-matter ischaemia. Unlike Alzheimer's, VaD has effectively no phase-3 RCT of rTMS or PEMF. Most cognitive-stimulation trials either exclude VaD or pool it with mixed dementia. The 2020 Lefaucheur European guideline makes no recommendation. Small case series suggest possible cognitive benefit; the evidence is insufficient for clinical claims. The interventions with the strongest disease-modifying signal in VaD remain aggressive vascular risk-factor optimisation — blood pressure, lipids, diabetes, atrial fibrillation, antiplatelet therapy where indicated, and lifestyle factors (exercise, smoking, diet). NICE NG97 applies; rTMS is not recommended outside a clinical trial. Low-intensity consumer PEMF has no human RCT in VaD.
Quick facts
- Best-supported intervention: Vascular risk-factor optimisation — BP, lipids, glycaemic control, AF management, antiplatelets where indicated
- rTMS evidence: No phase-3 RCT specifically in VaD; small case series only
- PEMF evidence: No human sham-controlled trial in VaD
- Lefaucheur 2020: No recommendation for VaD
- NICE NG97: Applies to all dementias — rTMS not recommended outside a trial
- Standard care: Memory clinic referral, vascular workup, secondary stroke prevention
Why the evidence is so thin
Three reasons VaD has so much less rTMS and PEMF evidence than Alzheimer's:
1. Trial recruitment
VaD diagnosis is harder than Alzheimer's. The NINDS-AIREN, VASCOG and DSM-5 criteria require both cognitive impairment and demonstrable cerebrovascular disease on imaging or clinical history. Pure VaD is less common than mixed dementia; in practice most large cognitive-stimulation trials either restrict to Alzheimer's or accept "AD with mixed pathology" but exclude pure VaD. The Sabbagh 2020 NeuroAD pivotal trial, the Koch 2022 precuneus trial, and the Wei 2024 null trial were all AD-only.
2. Heterogeneous pathology
VaD ranges from strategic single-infarct dementia to small-vessel disease with diffuse white-matter change to multi-infarct dementia. The cortical-stimulation target that might suit one phenotype may not suit another. Without large samples, sub-phenotype-stratified rTMS trials are unaffordable.
3. Stronger competing evidence
Vascular risk-factor optimisation has the strongest evidence base of any intervention in any dementia. The SPRINT-MIND trial showed intensive blood-pressure control (target SBP <120 mmHg) reduced incident MCI. Lipid management, AF anticoagulation, glycaemic control, smoking cessation and physical activity all have disease-modifying signal. With those interventions established, the marginal case for adding an unproven rTMS or PEMF intervention is weaker than in pure Alzheimer's.
What this means in practice
A patient with a new VaD diagnosis should be in a memory clinic that also coordinates with their cardiologist or stroke clinic for the vascular workup. Antiplatelet decisions, blood-pressure targets, lipid targets, glycaemic targets and AF anticoagulation should all be reviewed. Cognitive stimulation therapy is NICE-recommended. Magnetic stimulation should be considered only in a research-trial context — if your consultant is aware of one and refers.
Where PEMF might still have a legitimate role
VaD households deal with stroke recovery, mobility, chronic pain, and high carer load. PEMF has acceptable evidence in some of these adjacent areas — chronic pain, sleep, stress — for the carer. It does not, on current evidence, treat the dementia itself.
Frequently asked questions
Is there any rTMS trial specifically for vascular dementia?
As of May 2026, no phase-3 RCT of rTMS specifically in vascular dementia is reported on the public registers. Small case series and pooled mixed-dementia analyses exist but are not adequate for clinical recommendation.
If my mum has both Alzheimer's and vascular changes, can she try rTMS?
Many real-world AD trial populations include mixed pathology by post-mortem standards. Some private clinics offer rTMS to mixed-dementia patients, but NICE NG97 still recommends against outside a trial. Ask the clinic for the specific evidence they are relying on and for written informed consent that acknowledges off-licence use.
What about PEMF for post-stroke cognitive recovery?
Some PEMF and rTMS research has been done in stroke motor recovery (separate from vascular dementia). For stroke-related cognitive impairment that has progressed to VaD, the evidence base is much thinner. The /stroke-recovery page covers the post-stroke evidence.
Will treating blood pressure help cognition in VaD?
Yes — intensive blood-pressure control has the strongest evidence base for slowing cognitive decline in vascular-pattern dementia. SPRINT-MIND (target SBP <120 mmHg) showed reduced incident MCI. This is the single highest-leverage intervention in a VaD care plan.
Can PEMF help post-stroke fatigue or mobility?
Some evidence exists in stroke recovery (motor cortex rTMS for arm function), but this is different from treating vascular dementia. See the /stroke-recovery page for a focused review.
Is consumer PEMF safer than rTMS in VaD?
Low-intensity consumer PEMF has fewer acute risks than clinical rTMS. But neither has clinical-trial evidence for treating VaD. Pacemaker, ICD and DBS exclusions still apply.
Should the GP refer to a memory clinic and a stroke clinic?
Yes — VaD usually warrants both. The memory clinic handles the cognitive trajectory and CST referral; the stroke or cardiology clinic handles vascular risk and antiplatelet/anticoagulant decisions.
Are anti-amyloid antibodies relevant in VaD?
Lecanemab and donanemab target amyloid pathology in Alzheimer's. They are not licensed for pure VaD. In mixed AD-VaD where amyloid is documented, they may be considered with the memory clinic.
Related dementia pages on PEMF UK
Looking for a PEMF clinic in the UK?
We list every credible PEMF therapy provider in the UK. Please remember: no UK clinic can legally claim to treat dementia with PEMF or rTMS.